Starling Oncology, Inc. (STLN) stock: key figures, P/E, revenue and dividend
Health Care · United States
Starling Oncology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 502.73 m USD |
| Operating income | -36.08 m USD |
| EBIT | -49.46 m USD |
| Net income | -60.61 m USD |
| Diluted EPS – continuing operations | -0.54 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Starling Oncology, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
More stocks
- Hangzhou Dadi Haiyang Environmental Protection Co. Ltd. (301068.SZ)
- Zhejiang Jianye Chemical Co Ltd (603948.SS)
- Shenzhen Genvict Technologies Co Ltd (002869.SZ)
- Qualipoly Chemical Corp (4722.TW)
- Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A (603137.SS)
- Suncha Technology Co Ltd (001211.SZ)
- Shenzhen Chuangyitong Technology Co.Ltd. (300991.SZ)
- Phathom Pharmaceuticals, Inc. (PHAT)
- Baotou Dongbao Bio-Tech Co Ltd (300239.SZ)
- Great Taipei Gas Corp (9908.TW)
- Unizyx Holding Corp (3704.TW)
- Aquestive Therapeutics, Inc. (AQST)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.